bioAffinity Technologies, Inc. (BIAF)

NASDAQ: BIAF · IEX Real-Time Price · USD
2.020
-0.060 (-2.88%)
At close: Mar 28, 2024, 4:00 PM
2.080
+0.060 (2.97%)
After-hours: Mar 28, 2024, 6:15 PM EDT
-2.88%
Market Cap 23.16M
Revenue (ttm) 321,489
Net Income (ttm) -7.24M
Shares Out 11.45M
EPS (ttm) -0.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 73,986
Open 2.050
Previous Close 2.080
Day's Range 1.960 - 2.050
52-Week Range 0.955 - 3.620
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date May 13, 2024

About BIAF

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas. [Read more]

Sector Healthcare
IPO Date Sep 1, 2022
Employees 14
Stock Exchange NASDAQ
Ticker Symbol BIAF
Full Company Profile

Financial Performance

Financial Statements

News

Wallachbeth Capital Announces Closing of bioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement

JERSEY CITY, N.J. , March 8, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, In...

20 days ago - PRNewsWire

bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies closed a securities purchase agreement with institutional investors for gross proceeds of approximately $2.5 million.

20 days ago - Business Wire

WallachBeth Capital Announces Pricing of BioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement

JERSEY CITY, N.J. , March 6, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that BioAffinity Technologies (NA...

22 days ago - PRNewsWire

bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces it has entered into a securities purchase agreement with institutional investors.

22 days ago - Business Wire

bioAffinity Technologies Reports Accelerating Sales Growth of CyPath® Lung

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports 375% growth in sales of CyPath Lung tests in recent months.

23 days ago - Business Wire

bioAffinity Technologies News Update

SAN ANTONIO--(BUSINESS WIRE)-- #ATS--bioAffinity Technologies shares the latest news updates about the company and its CyPath Lung noninvasive test for lung cancer.

5 weeks ago - Business Wire

Medical Director of Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Sandeep Bansal, M.D., Joins bioAffinity Technologies' Medical and Scientific Advisory Board and Incorporates CyPath® Lung into Medical Practice

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Sandeep Bansal, M.D., joins bioAffinity Medical and Science Advisory Board; adds CyPath Lung to his practice.

7 weeks ago - Business Wire

bioAffinity Technologies In The News

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Summary of the latest news about bioAffinity Technologies.

2 months ago - Business Wire

bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Indian Patent Office issues patent to bioAffinity Technologies for porphyrin compounds related to targeted cancer treatment.

2 months ago - Business Wire

bioAffinity Technologies In the News

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--A summary of latest news about bioAffinity Technologies and CyPath® Lung, its noninvasive test for the detection of early-stage lung cancer.

2 months ago - Business Wire

bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / January 5, 2024 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (NASDAQ:BIAF) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Mone...

Other symbols: BIVI
2 months ago - Accesswire

bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Jamie Platt, Ph.D., joins the bioAffinity Technologies Board of Directors.

4 months ago - Business Wire

CMS Posts Final Payment Determination for bioAffinity Technologies' CyPath® Lung Effective January 2024

SAN ANTONIO,--(BUSINESS WIRE)-- #BIAF--CMS has made a final determination for payment for CyPath® Lung, a noninvasive test for early-stage lung cancer, for the 2024 calendar year.

4 months ago - Business Wire

bioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology Post

SAN ANTONIO--(BUSINESS WIRE)-- #ASCB--bioAffinity Technologies VP of Research David Elzi, Ph.D., named to post with the American Society for Cell Biology.

4 months ago - Business Wire

bioAffinity Technologies Teams with American Cancer Society to Raise Funds for Lung Cancer Screening

SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies today launched a campaign in partnership with the ACS to increase lung cancer screening in Texas.

4 months ago - Business Wire

bioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports third quarter 2023 financial results and provides business update.

4 months ago - Business Wire

bioAffinity Technologies Names Dallas J. Coleman as National Director of Sales

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces the appointment of Dallas Coleman as National Director of Sales.

5 months ago - Business Wire

bioAffinity Technologies to Present at the 8th Annual Dawson James Small Cap Growth Conference

SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies presents at Dawson James Small Cap Growth Conference this week.

6 months ago - Business Wire

bioAffinity Technologies Acquires Laboratory Assets of Precision Pathology Services

SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies, Inc. (Nasdaq: BIAF, BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer, ann...

6 months ago - Business Wire

bioAffinity Technologies to Participate in the H.C. Wainwright Global Investment Conference

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity President and CEO Maria Zannes will present at H.C. Wainwright Global Investment Conference Sept. 11-13.

7 months ago - Business Wire

bioAffinity Technologies Reports Second Quarter 2023 Financial Results and Provides Business Update

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports second quarter 2023 financial results and provides business update.

8 months ago - Business Wire

AMA Issues CPT Code for bioAffinity Technologies' CyPath® Lung Test for Early-Stage Lung Cancer

SAN ANTONIO, Texas--(BUSINESS WIRE)-- #AMA--The AMA has issued a CPT code specifically for bioAffinity Technologies' CyPath® Lung noninvasive test for early-stage lung cancer.

9 months ago - Business Wire

bioAffinity Technologies Presents Research Findings at UMass RNA Therapeutics Symposium

SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies presents research at UMass 5th annual RNA Therapeutics Symposium June 21-23.

10 months ago - Business Wire

bioAffinity Technologies Presents Research Findings at CYTO 2023

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies presents research findings at CYTO 2023.

11 months ago - Business Wire

bioAffinity Technologies Reports First Quarter 2023 Financial Results

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies releases first quarter 2023 financial results and reports progress on CyPath Lung diagnostic.

11 months ago - Business Wire